FM101

FM101 is an investigational small molecule selective antagonist of the A3 adenosine receptor (A3AR) being developed by the South Korean biotechnology company Future Medicine Ltd. The drug is primarily targeted at metabolic liver diseases, specifically non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). By selectively antagonizing the A3AR, which is often overexpressed in inflammatory and fibrotic tissues, FM101 is designed to exert anti-inflammatory and anti-fibrotic effects in the liver. It has undergone Phase 1 clinical evaluation for safety, tolerability, and pharmacokinetics in healthy volunteers and has advanced into Phase 2a trials to evaluate its efficacy in reducing liver fat and inflammation in patients with NAFLD/NASH. The drug is administered as an oral solution.

Other names

FM101FM-101FM 101